Reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters.

Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: D.H.B is a co-inventor on provisional vaccine patents (63/121,482; 63/133,969; 63/135,182). The Boon laboratory has received unrelated funding support in sponsored research agreements from AI Therapeutics, GreenLight Biosciences Inc., and Nano targeting & Therapy Biopharma Inc. The Boon laboratory has received funding support from AbbVie Inc., for the commercial development of SARS-CoV-2 mAb. M.S.D. is a consultant for Inbios, Vir Biotechnology, Senda Biosciences, and Carnival Corporation, on the Scientific Advisory Boards of Moderna and Immunome, and has licensed mucosal vaccine technology to Bharat Biotech and Ocugen. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Vir Biotechnology, Kaleido, and Emergent BioSolutions and past support from Moderna not related to these studies. The authors report no other conflict of interest.